• 한국농림기상학회지
• /
• 제3권2호
• /
• pp.88-95
• /
• 2001

경기도 광주지역의 잣나무, 낙엽송, 활엽수 임분에 있어서 pH 및 용존 원소의 수직적인 이동특성을 구명하기 위하여 강우의 지속에 따른 임외우와 임내우 pH와 강우 중 화학적 조성을 각 단계별로 분할 채취하여 조사, 분석한 결과를 요약하면 다음과 같다. 임외우의 pH의 범위는 4.67~6.72였으며, 평균 pH는 5.74$\pm$0.62로 나타났다. 임외우의 pH와 수관통과우 및 수간류 pH와의 관계를 보면, 임외우 pH에 대한 수종차이 즉, 침엽수에 비하여 임외우의 산성화에 대한 완충능의 수종 특성이 존재하고 있음을 알 수 있었다. 또한, 수종에 따라서 산성화 경향의 수간류와 알칼리화 경향의 수간류가 있어 수종에 따라서 수간류의 pH 변화에 대한 특성을 보였다. 각 수종별 초기강우와 후속강우의 변화를 보면, 활엽수림은 수간류에서 1998년 10월과 1999년 4월, 수관통과우에서는 1998년 8월을 제외하고는 초기강우의 pH 변화 폭이 크게 나타났으나, 후속강우의 pH는 5.20~6.90의 일정한 범위 내에서 변화하였다. 후속 강우가 초기 강우시 양이온의 영향을 많이 받는 것과는 달리 S $O_{4}$$^{2-}$ , N $O_{3}$$^{-}$, C $l^{-}$등 음이온의 영향을 많이 받으며, 음이온 성분 등은 가스상이나 미세입자로 존재함으로 강우량이 증가함에도 지속적으로 세정되어 후속 강우에 영향을 주는 것으로 볼 수 있다.

• Asian-Australasian Journal of Animal Sciences
• /
• 제30권7호
• /
• pp.985-993
• /
• 2017

Objective: The objective of this study was to evaluate increasing doses of a novel microbial phytase (Cibenza Phytaverse, Novus International, St. Charles, MO, USA) on standardized total tract digestibility (STTD) of P in canola meal (CM), corn, corn-derived distiller's dried grains with solubles (DDGS), rice bran (RB), sorghum, soybean meal (SBM), sunflower meal (SFM), and wheat. Methods: Two cohorts of 36 pigs each (initial body weight = $78.5{\pm}3.7kg$) were randomly assigned to 2 rooms, each housing 36 pigs, and then allotted to 6 diets with 6 replicates per diet in a randomized complete block design. Test ingredient was the only dietary source of P and diets contained 6 concentrations of phytase (0, 125, 250, 500, 1,000, or 2,000 phytase units [FTU]/kg) with 0.4% of $TiO_2$ as a digestibility marker. Feeding schedule for each ingredient was 5 d acclimation, 5 d fecal collection, and 4 d washout. The STTD of P increased (linear or exponential $p{\leq}0.001$) with the inclusion of phytase for all ingredients. Results: Basal STTD of P was 37.6% for CM, 37.6% for corn, 68.6% for DDGS, 10.3% for RB, 41.2% for sorghum, 36.7% for SBM, 26.2% for SFM, and 55.1% for wheat. The efficiency of this novel phytase to hydrolyze phytate is best described with a broken-line model for corn, an exponential model for CM, RB, SBM, SFM, and wheat, and a linear model for DDGS and sorghum. Based on best-fit model the phytase dose (FTU/kg) needed for highest STTD of P (%), respectively, was 735 for 64.3% in CM, 550 for 69.4% in corn, 160 for 55.5% in SBM, 1,219 for 57.8% in SFM, and 881 for 64.0% in wheat, whereas a maximum response was not obtained for sorghum, DDGS and RB within the evaluated phytase range of 0 to 2,000 FTU/kg. These differences in the phytase concentration needed to maximize the STTD of P clearly indicate that the enzyme does not have the same hydrolysis efficiency among the evaluated ingredients. Conclusion: Variations in enzyme efficacy to release P from phytate in various feedstuffs need to be taken into consideration when determining the matrix value for phytase in a mixed diet, which likely depends on the type and inclusion concentration of ingredients used in mixed diets for pigs. The use of a fixed P matrix value across different diet types for a given phytase concentration is discouraged as it may result in inaccurate diet formulation.

• Journal of Pharmaceutical Investigation
• /
• 제36권5호
• /
• pp.343-348
• /
• 2006

The purpose of the present study was to evaluate the bioequivalence of two zolpidem tartrate tablets, Stilnox tablet(Sanofi-aventis Korea, reference product) and Zanilo tablet(ChoDang Pharm Co., Ltd., Korea, test product), according to the guidelines of Korea Food and Drug Administration(KFDA). After adding an internal standard(cimetropium), 250 ${\mu}L$ plasma samples were extracted using 1.3 mL of ethyl acetate. Extracted compounds were analyzed by HPLC with triple-quadrupole mass spectrometry. This method for determination of zolpidem is proved accurate and reproducible with the limit of quantitation of 1 ng/mL in human plasma. Twenty-four healthy male Korean volunteers received each medicine at the zolpidem tartrate dose of 10 mg in a $2{\times}2$ crossover study. There was one-week washout period between the doses. Plasma concentrations of zolpidem were monitored for over a period of 8 hr after the administration. $AUC_{0-t}$(the area under the plasma concentration-time curve) was calculated by the linear trapezoidal rule. $C_{max}$(maximum plasma drug concentration) and $T_{max}$(time to reach $C_{max}$) were compiled from the plasma concentration-time data. Analysis of variance was carried out using logarithmically transformed $AUC_{0-t}$ and $C_{max}$. No significant sequence effect was found for all of the bio-availability parameters indicating that the crossover design was properly performed. The 90% confidence intervals for the log transformed data were acceptable range of log 0.8 to log 1.25(e.g., log 0.92-log 1.06 for $AUC_{0-t}$, log 0.96-log 1.13 for $C_{max}$). The major parameters, $AUC_{0-t}$ and $C_{max}$ met the criteria of KFDA for bioequivalence indicating that Zanilo tablet is bioequivalent to Stilnox tablet.

• Journal of Pharmaceutical Investigation
• /
• 제41권3호
• /
• pp.191-196
• /
• 2011

In this study simple and sensitive high performance liquid chromatographic method using a commercially available column, was developed and validated for the determination of zolpidem tartrate in human plasma. The developed method with suitable validation was applied to a bioequivalence study of two different kinds of zolpidem tartrate. Two different formulations containing 10 mg of zolpidem tartate (CAS : 99294-93-6) were compared in 24 healthy male volunteers in order to compare the bioavailability and prove the bioequivalence. The study was performed in an open, single dose randomized, 2-sequence, cross-over design in 24 healthy male volunteers with a one-week washout period. Blood samples for pharmacokinetic profiling were drawn at selected times during 12 h. The mean $AUC_{0-12h}$, $C_{max}$, $T_{max}$ and $T_{1/2}$ were $676.6{\pm}223.4$ $ng{\cdot}h{\cdot}mL^{-1}$, $177.4{\pm}34.2$ $ng{\cdot}mL^{-1}$, and $0.8{\pm}0.4$ and $3.5{\pm}2.1$, respectively, for the test formulations, and $640.7{\pm}186.6$ $ng{\cdot}h{\cdot}mL^{-1}$, $193.0{\pm}64.5$ $ng{\cdot}mL^{-1}$, and $0.9{\pm}0.4$ and $2.7{\pm}0.9$, respectively, for the reference formulation. Both primary target parameters $AUC_{0-12h}$ and $C_{max}$ were log-transformed and tested parametrically by analysis of variance (ANOVA). 90% confidence intervals of $AUC_{0-12h}$ and $C_{max}$ were in the range of acceptable limits of bioequivalence (80-125%). Based on these results, the two formulations of zolpidem tartate are considered to be bioequivalent.

• Journal of Pharmaceutical Investigation
• /
• 제38권6호
• /
• pp.421-427
• /
• 2008

The purpose of the present study was to evaluate the bioequivalence of two etodolac capsules, Kuhnillodin capsule (Kuhnil. Co., Ltd., Seoul, Korea) as reference drug and Etodin capsule (Myungmun Pharm. Co., Ltd., Seoul, Korea) as test drug, according to the guidelines of Korea Food and Drug Administration (KFDA). Twenty-three healthy male Korean volunteers received one capsule at the dose of 200 mg etodolac in a $2{\times}2$ crossover study. There was a one-week washout period between the doses. Plasma concentrations of etodolac were monitored by a high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) for over a period of 24 hr after the administration. $AUC_{0-24\;hr}$ was calculated by the linear trapezoidal rule method. $C_{max}$ and $T_{max}$ were compiled from the plasma concentration-time data. Analysis of variance (ANOVA) was carried out using logarithmically transformed $AUC_{0-24\;hr}$ and $C_{max}$. The 90% confidence intervals of the $AUC_{0-24\;hr}$ ratio and the $C_{max}$ ratio for Etodin/Kuhnillodin were $\log\;0.97{\sim}\log\;1.08$ and $\log\;0.89{\sim}\log\;1.19$, respectively. These values were within the acceptable bioequivalence intervals of $\log\;0.80{\sim}\log\;1.25$. Thus, our study demonstrated that Etodin was bioeqiovalent to Kuhnillodin preparation when the rate and extent of absorption between two preparations were compared.

• 한국임상약학회지
• /
• 제8권2호
• /
• pp.107-112
• /
• 1998

Lovastatin is a lipid lowering agent for the treatment of hypercholesterolemia and belongs to a new class of pharmacologic compounds called the 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors. By competitively inhibiting HMG CoA reductase, lovastatin disrupts the biosynthesis of cholesterol in hepatic and peripheral cells and increases the synthesis of high-density-lipoprotein HDL) receptors. Following oral administration, the lactone ring of lovastatin is hydrolysed to the active inhibitor of HMG CoA reductase, lovastatin acid. Lovastatin is known to have poor oral absorption and wide individual variation. In this study, bioequivalence test of two lovastatin formulations, the test drug ($Lovaload^{TM}$, Chong Kun Dang Pharmaceutical Co.) and the reference drug ($Mevacor^{TM}$, Chung Wae Pharmaceutical Co.) were conducted according to the guidelines of Korea Food and Drug Administration (KFDA). A total of 18 healthy male volunteers, $31.90\pm3.60$ years old and $72.17\;7.88$ kg of body weight in average, were evaluated in a randomized crossover manner with a 2-week washout period. Concentrations of lovastatin acid in plasma were measured upto 12 hours following a single oral administration of eight tablets (20 mg of lovastatin per tablet) by high-performance liquid chromatography with UV detection at 238 nm. The area under the concentration-vs-time curve from 0 to 12 hours $(AUC_{0-12h})$ was calculated by the trapezoidal summation method. The statistical analysis showed that there are no significant differences in $AUC_{0-12h),\;C_{max}\;and\;T_{max}$ between the two formulations ($6.72\%,\;1.52\%,\;and\;0.88\$, respectively). The least significant differences between the formulations at $\alpha$=0.05 were less than $20\%\;(11.65\%,\;19.73\%,\;and\;14.81\%\;for\;AUC_{0-12h},\;C_{max}\;and\;T_{max}$, respectively). The $90\%$ confidence intervals for these parameters were also within $\pm20\%\;(-1.50{\leq}{\delta}{\leq}15.00$, $-12.50{\leq}{\delta}{\leq}15.50,\;and\;-9.64{\leq}{\delta]{\leq}11.40{\leq}\;for\;\;AUC_{0-12h}$ ,$C_{max}\;and\;T_{max}$, respectively). In conclusion, the new generic product $Lovaload^{TM}$ was proven to be bioequivalent with the reference drug.

• Journal of Acupuncture Research
• /
• 제30권3호
• /
• pp.39-49
• /
• 2013

Objectives : The purpose of this study is to assess the effect of Taegeuk acupuncture on reducing mental stress by analyzing heart rate variability in Soeumin. Methods : Six Soeumin-diagnosed men participated in this study. They were randomly divided into group A and group B. Each participant went through 4 sessions every week with 1 week of washout period in between each session. HRV was measured three times at every session; at baseline, after administering mentally stressful circumstances and after applying Soeumin Taegeuk acupuncture or Soyangin Taegeuk acupuncture. This study was designed as a crossover clinical trial. Group A participants were treated with two sets of Soeumin Taegeuk and Soyangin Taegeuk acupuncture treatment in respective order (i.e. Soeumin Taegeuk - Soyangin Taegeuk - Soeumin Taegeuk - Soyangin Taegeuk acupuncture treatment). Group B participants were treated with reverse-ordered acupuncture treatment (i.e. Soyangin Taegeuk - Soeumin Taegeuk - Soyangin Taegeuk - Soeumin Taegeuk acupuncture treatment ). Bayesian analysis was performed by using WinBUGS(Ver. 1.4.3) for comparison between Soeumin Taegeuk acupuncture and Soyangin Taegeuk acupuncture. Results : Overall, Soeumin Taegeuk acupuncture tends to reduce LF/HF ratio, LF, HF, LF(Norm) and increase HF(Norm) more than Soyangin Taegeuk acupuncture, but the difference was not statistically significant. In one participant, however, Soeumin Taegeuk acupuncture reduced LF/HF ratio, LF(Norm) and increased HF(Norm) more than Soyangin Taegeuk acupuncture, and the difference was stastatistically significant. Conclusions : This study suggests that Soeumin Taegeuk acupuncture might be an effective means of stabilizing mental stress-induced imbalance of autonomic nervous system for Soeumin.

• Archives of Pharmacal Research
• /
• 제21권4호
• /
• pp.411-417
• /
• 1998

In order to investigate the effect of the pretreatment with various doses of diltiazem (DTZ) on the pharmacokinetics of indocyanine green (ICG) at steady state, especially the hepatic blood clearance due to the change of hepatic blood flow, the following experiments were carried out with ICG, a hepatic function test marker, not metabolized in liver and only excreted in bile. The intravenous bolus injection ($3,780\mu\textrm{g}$/kg) and the constant-rate infusion ($10,100\mu\textrm{g}$/kg/hr) of ICG into the left femoral vein were made in order to check the steady-state plasma concentration ($C_{ss} of $10\mu\textrm{g}$/ml) of ICG at 20, 25 and 30 min. Following a 90-min washout period, the intravenous bolus injection (108, 430, 860 and $1,720\mu\textrm{g}$/kg) and the constant-rate infusion (108, 433, 866 and $1,730\mu\textrm{g}$/kg/hr) of DTZ into the right femoral vein were made and the achievement of the steady-state plasma levels ($C_{ss} of 50, 200, 400 and 800 ng/ml) of DTZ were conformed at 60, 70 and 80 min. During the steady state of DTZ, the intravenous bolus injection ($3,780\mu\textrm{g}$/kg) and the constant-rate infusion ($10,200\mu\textrm{g}$/kg/hr) of ICG into the left femoral vein were made and also the steady-state plasma concentration of ICG was checked at 20, 25 and 30 min. The plasma concentrations of DTZ and ICG were determined using a high performance liquid chromatographic technique. At the steady state, the hepatic blood clearance of ICG was obtained from the plasma concentration and blood-to-plasma concentration ratio ($R_B$) of ICG. The pretreatment with various doses of DTZ did not influence the plasma concentrations, $R_B$ and plasma free fraction ($f_p$) of ICG. So the hepatic blood clearance of ICG was independent of concentration of DTZ. The hepatic blood clearance of ICG could be affected by both hepatic bood flow and hepatic intrinsic clearance. But there was no change of the hepatic blood clearance of ICG between the control and the DTZ-pretreated rats in this study. So it may be suggested that DTZ does not influence hepatic blood flow.

• 콘크리트학회논문집
• /
• 제26권6호
• /
• pp.679-686
• /
• 2014

본 연구에서는 광물질 혼화재료를 사용한 수중불분리성 콘크리트의 물성을 만족하면서 수중불분리성 혼화제의 사용량을 줄이기 위한 배합적 접근과 수중불분리성 콘크리트의 시험에 있어 실무와 차이가 있는 사항에 대하여 검토를 실시하였는데, 그 결과를 요약하면 다음과 같다. 우선 광물질 혼화재료를 사용하는 수중불분리성 콘크리트의 최적 단위수량 및 수중불분리성 혼화제의 사용량은 190 kg, 0.9%/W인 것으로 나타났으며, 특히 목표강도의 W/B에서 5% 정도로 낮춘 W/B로 배합설계를 통해 단위수량 및 수중불분리성 혼화제 사용량을 줄여 W/B 조절에 따른 재료분리저항성, 압축강도 등의 품질 확보 및 경제성의 확보가 가능할 것으로 판단된다. 또한, 탁도계를 이용한 혼탁물질량의 측정을 위해서는 탁도계 검침부 삽입 후 1분 경과 시점에서 안정적인 값을 나타냈으나, 수중불분리성 콘크리트의 혼탁물질량을 측정하기 위해 실무에서 사용되는 탁도계와 KCI -AD102 표준방법과의 상관성에 대한 부분의 검토가 필요할 것으로 판단된다. 수중 공시체 제작방법에 따른 압축강도의 발현성은 크게 차이가 없는 것으로 나타났다.

• Journal of Pharmaceutical Investigation
• /
• 제37권6호
• /
• pp.397-402
• /
• 2007

To evaluate the bioequivalence of two venlafaxine formulations, a standard 2-way randomized cross-over study was conducted in twenty-four healthy male Korean volunteers. A single oral dose of 75 mg of test formulation Venfaxine $OR^{(R)}$ (tablet) or reference formulation Efexor $XR^{(R)}$ (capsule) was administered with one-week washout period. Plasma concentrations of venlafaxine were assayed for over a period of 72 hours with a well validated method using liquid chromatography coupled to tandem mass spectrometry (LC-MS-MS). The $mean{\pm}S.D$. of maximum concentration $(C_{max})$ and elimination half-life $(t_{1/2})$ were $64.7{\pm}28.5$ ng/mL, $9.2{\pm}3.0$ h, and $67.2{\pm}30.2$ ng/mL, $9.9{\pm}3.5$ h for test and reference formulations, respectively. Time to reach maximum concentration $(T_{max})$ expressed in median value (range), for the test and the reference, were 10 h (6-14) and 8h (4-12), respectively. Similarly, area under the plasma concentration-time curve, from time zero to last sampling time $(AUC_t)$ and from time zero to time infinity $(AUC_{inf})$, for test and reference formulations were $1185{\pm}755$, $1326{\pm}896$ and $1124{\pm}737$, $1185{\pm}755$ $ng{\cdot}h/mL$, respectively. The parametric 90% confidence intervals on the mean of the differences between the two formulations (test-reference) of the log transformed values of $AUC_t$, and $C_{max}$ were 0.9630 to 1.1383 and 0.8650 to 1.0446, respectively. The overall results indicate that the two formulations are bioequivalent and can be prescribe interchangeably.